literature

HIV mutation literature information.

Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.

PMID: 33014372 2020 SAGE open medicine

Table: Y188L

Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.

PMID: 29846534 2019 Clinical infectious diseases

Result: The mutations K103N/S, Y181C, Y188L, and G190A accounted for 88.5% of the 348 NNRTI SDRMs.

Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.

PMID: 31778107 2019 Current HIV research

Discussion: It was also found that the PDR rate did not significantly differ among the three main subtypes (CRF07_BC, CRF08_BC and CRF01_AE); however, in a previous study, HIV-1 CRF07_BC showed distinctive resistance evolution pathways in which the mutations K103N, Q197K, V179D and Y188L were the major resistance mutations.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.

PMID: 30476106 2019 The Journal of antimicrobial chemotherapy

Abstract: The most prevalent mutations were V108I (n = 62; 0.6%), Y188L (n = 18; 0.2%), H221Y (n = 18; 0.2%) and Y318F (n = 23; 0.2%).

Abstract: We studied the prevalence of doravirine resistance-associated mutations previously identified in vitro: V106A/M, V108I, Y188L, V190S, H221Y, F227C/L/V, M230I/L, L234I, P236L, Y318F and K103N/Y181C.

Effect of alpha-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.

PMID: 30525601 2019 Journal of medicinal chemistry

1Abstract: The various alpha-methoxy DABO series (12-14) present different SAR at the dihalo benzyl substitution, with the most potent compounds (12d,e and 13c) showing similar (picomolar/nanomolar) anti-HIV-1 potency as the corresponding alpha-methyl analogues against wt HIV-1, and 10-100-fold increased potency (up to low nanomolar) against clinically relevant K103N, Y181C, Y188L, IRLL98, and K103N+Y181C HIV-1 mutant strains, highlighting the importance of the alpha-methoxy substitution to provide highly efficient DABOs as ""second generation"" NNRTIs."

Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.

PMID: 30621727 2019 Virology journal

Discussion: We observed that NNRTI mutations principally occurred in the first and second periods of treatment failure and were mainly K103 N/R/S, V179D/E, Y181C/I/V, G190A, Y188L/C.

Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

PMID: 30624934 2019 Journal of medicinal chemistry

Result: As noted above, 13c2 can inhibit single (L100I, K103N, Y181C, Y188L, E138K) and double (F227+V106A) mutated HIV-RT variants (see Figure S3 for the location of these mutations).

Result: Five mutations (L100I, Y181C, Y188L, F227L, and V106) are located in the hydrophobic pocket that accommodates the benzonitrile and benzamide moieties of the ligand.

Result: In the case of L100I, Y181C, Y188L, and E138K, 13c2, 13c3, and 13c4 provided single-digit nanom

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance.

PMID: 30648124 2019 Open forum infectious diseases

Conclusion: At that time, resistance testing showed NRTI (M184V, T69D, T215S, D67N, K219Q), NNRTI (Y181C, Y188L, H221Y) and PI (L10I, D30N, K20T, L33F, K43T, N88D) resistance, with PI resistance to nelfinavir.

Table: Y188L

Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.

PMID: 30650082 2019 PloS one

Result: For a number of TDRMs, no loss could be observed during the observation period (S1 Table) and, according to their maximal duration of observation, the following TDRMs seem to survive for lengthy periods in the absence of ART: the NRTI resistance mutations D67N (5.9 years), K70R (6.9 years), F77L (10.2 years), T215E (5.9 years) and K219Q (5.9 years), the NNRTI resistance mutations A98G (6.5 years) and Y188L (5.9 years) as well as the PI mutations I54L (5.9 years) and L90M (8.4 years) (S1 Table).

Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.

PMID: 31443633 2019 BMC infectious diseases

Result: For NNRTIs, the most prevalent drug resistance mutations were K103 N (1.59%), V179D + K103R (1.33%), Y181C (0.80%), V108I (0.53%), Y188L (0.53%), G190A (0.53%), H221Y (0.53%), Y318F (0.53%), A98G (0.27%), V106A (0.27%), E138A (0.27%), E138R (0.27%), Y188C (0.27%) and M230 L (0.27%).

Browser Board

Co-occurred Entities

Filtrator